Vantrela Er is a drug owned by Teva Branded Pharmaceutical Products R And D Inc. It is protected by 3 US drug patents filed in 2017 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 31, 2029. Details of Vantrela Er's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8445018 | Abuse resistant drug formulation |
Jul, 2029
(4 years from now) | Active |
| US9572803 | Abuse resistant drug formulation |
Sep, 2027
(2 years from now) | Active |
| US9216176 | Abuse resistant drug formulation |
Sep, 2027
(2 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Vantrela Er's patents.
Latest Legal Activities on Vantrela Er's Patents
Given below is the list of recent legal activities going on the following patents of Vantrela Er.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 29 Jan, 2024 | US9216176 |
| Maintenance Fee Reminder Mailed Critical | 14 Aug, 2023 | US9216176 |
| Expire Patent Critical | 28 Jun, 2021 | US8445018 |
| Expire Patent Critical | 29 Mar, 2021 | US9572803 |
| Maintenance Fee Reminder Mailed Critical | 11 Jan, 2021 | US8445018 |
| Maintenance Fee Reminder Mailed Critical | 12 Oct, 2020 | US9572803 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 07 Jun, 2019 | US9216176 |
| Patent Issue Date Used in PTA Calculation Critical | 21 Feb, 2017 | US9572803 |
| Recordation of Patent Grant Mailed Critical | 21 Feb, 2017 | US9572803 |
| Email Notification Critical | 02 Feb, 2017 | US9572803 |
US patents provide insights into the exclusivity only within the United States, but Vantrela Er is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Vantrela Er's family patents as well as insights into ongoing legal events on those patents.
Vantrela Er's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Vantrela Er's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 31, 2029 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Vantrela Er Generic API suppliers:
Hydrocodone Bitartrate is the generic name for the brand Vantrela Er. 1 company has already filed for the generic of Vantrela Er. Check out the entire list of companies who have already received approval for Vantrela Er's generic
Alternative Brands for Vantrela Er
There are several other brand drugs using the same active ingredient (Hydrocodone Bitartrate) as Vantrela Er. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Abbvie |
| |
| Purdue Pharma Lp |
| |
| Recro Gainesville |
| |
| Sovereign Pharms |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Hydrocodone Bitartrate, Vantrela Er's active ingredient. Check the complete list of approved generic manufacturers for Vantrela Er
About Vantrela Er
Vantrela Er is a drug owned by Teva Branded Pharmaceutical Products R And D Inc. Vantrela Er uses Hydrocodone Bitartrate as an active ingredient. Vantrela Er was launched by Teva Branded Pharm in 2017.
Approval Date:
Vantrela Er was approved by FDA for market use on 17 January, 2017.
Active Ingredient:
Vantrela Er uses Hydrocodone Bitartrate as the active ingredient. Check out other Drugs and Companies using Hydrocodone Bitartrate ingredient
Dosage:
Vantrela Er is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 30MG | TABLET, EXTENDED RELEASE | Discontinued | ORAL |
| 45MG | TABLET, EXTENDED RELEASE | Discontinued | ORAL |
| 60MG | TABLET, EXTENDED RELEASE | Discontinued | ORAL |
| 90MG | TABLET, EXTENDED RELEASE | Discontinued | ORAL |
| 15MG | TABLET, EXTENDED RELEASE | Discontinued | ORAL |